InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

Current share price for CHM : $0.042 0.001 (2.44%)+

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2 Application for quotation of securities - CHM 25 Jul 2025 10:10AM $0.004 $0.042 risen by 950%
$2 Update - Proposed issue of securities - CHM 24 Jul 2025 8:39AM $0.005 $0.042 risen by 740%
$2 Proposed issue of securities - CHM 23 Jul 2025 5:03PM $0.005 $0.042 risen by 740%
$2 Prospectus 23 Jul 2025 4:33PM $0.005 $0.042 risen by 740%
$2 Results of Meeting 23 Jul 2025 12:12PM $0.005 $0.042 risen by 740%
$2 Presentation to Extraordinary General Meeting 23 Jul 2025 8:45AM $0.005 $0.042 risen by 833.33%
$2 Initial Director's Interest Notice 2 Jul 2025 5:07PM $0.005 $0.042 risen by 833.33%
$2 Change of Director's Interest Notice LR 1 Jul 2025 4:57PM $0.005 $0.042 risen by 833.33%
$2 Professor Miles Prince appointed as Non-Executive Director 1 Jul 2025 8:35AM $0.004 $0.042 risen by 950%
$2 Notification of cessation of securities - CHM 26 Jun 2025 4:14PM $0.004 $0.042 risen by 950%
$2 Notice of Extraordinary General Meeting/Proxy Form 24 Jun 2025 8:32AM $0.004 $0.042 risen by 950%
$2 Translational data shows persistence of CHM CDH17 17 Jun 2025 8:29AM $0.004 $0.042 risen by 950%
$2 Chimeric receives $2.5 M advance on FY25 R&D tax incentive 10 Jun 2025 12:20PM $0.004 $0.042 risen by 950%
$2 CHM CDH17 receives FDA Fast Track 4 Jun 2025 9:47AM $0.004 $0.042 risen by 950%
$2 Application for quotation of securities - CHM 29 May 2025 4:52PM $0.004 $0.042 risen by 950%
$2 Change in substantial holding - PH 28 May 2025 4:15PM $0.004 $0.042 risen by 950%
$2 Application for quotation of securities - CHM 26 May 2025 3:26PM $0.004 $0.042 risen by 950%
$2 Letter to Shareholders 26 May 2025 2:05PM $0.004 $0.042 risen by 950%
$2 Prospectus 26 May 2025 9:39AM $0.004 $0.042 risen by 950%
$2 Presentation to investor webinar 22 May 2025 9:27AM $0.005 $0.042 risen by 740%
$2 CHM CDH17 ADVANCES TO DOSE LEVEL 2 21 May 2025 9:38AM $0.005 $0.042 risen by 740%
$2 Investor webinar 20 May 2025 4:51PM $0.005 $0.042 risen by 740%
$2 Proposed issue of securities - CHM 20 May 2025 11:26AM $0.008 $0.042 risen by 425%
$2 Proposed issue of securities - CHM 20 May 2025 11:26AM $0.008 $0.042 risen by 425%
$2 $6.6 million Placement to advance clinical trial pipeline 20 May 2025 11:26AM $0.008 $0.042 risen by 425%

101 - 125 of 640 results

Page 5 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.